Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review.
about
Mirtazapine (adjunct) versus placebo for schizophreniaMutant mouse models: genotype-phenotype relationships to negative symptoms in schizophreniaA placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophreniaRepetitive transcranial magnetic stimulation (rTMS) for treating major depression and schizophrenia: a systematic review of recent meta-analysesNMDA and dopamine converge on the NMDA-receptor to induce ERK activation and synaptic depression in mature hippocampusDevelopmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model.The effects of galantamine on psychopathology in chronic stable schizophrenia.Methodological issues in negative symptom trialsAn Integrative Perspective on the Role of Dopamine in SchizophreniaRisk of osteoporosis and fracture incidence in patients on antipsychotic medication.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia.Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor.Insight in schizophrenia: relationship to positive, negative and neurocognitive dimensions.Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials.Social cognition as an RDoC domain.Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia.Validation of the Korean-Version of the Clinical Assessment Interview for Negative Symptoms of Schizophrenia (CAINS).Glutamate and dopamine in schizophrenia: an update for the 21st centuryA review of repetitive transcranial magnetic stimulation use in the treatment of schizophrenia.Deficit schizophrenia: an update.Synaptic and cellular changes induced by the schizophrenia susceptibility gene G72 are rescued by N-acetylcysteine treatment.Deficits in reinforcement learning but no link to apathy in patients with schizophrenia.Effectiveness and tolerability of warm-supplementing kidney yang added to risperidone in improving cognitive impairment in patients with schizophrenia: An 8-week, multicenter, randomized, double-blind, placebo-controlled clinical trial.Beyond the first episode: candidate factors for a risk prediction model of schizophrenia.Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia.Policy and service development implications of the second Australian National Survey of High Impact Psychosis (SHIP).Genetic models of schizophrenia and related psychotic disorders: progress and pitfalls across the methodological "minefield".Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophreniaTreatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.Genetic Deletion of Akt3 Induces an Endophenotype Reminiscent of Psychiatric Manifestations in Mice.Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI.Discovery of Oxazolobenzimidazoles as Positive Allosteric Modulators for the mGluR2 Receptor.A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial.Efficacy of bilateral repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: results of a multicenter double-blind randomized controlled trial.Psychiatrists' attitude towards and knowledge of clozapine treatment.Effects of naltrexone on food intake and body weight gain in olanzapine-treated rats.Negative Symptoms and Reward Disturbances in Schizophrenia Before and After Antipsychotic Monotherapy.
P2860
Q24188248-2C8D2321-B256-422F-863C-B90F6F420AD5Q24632939-8BFC086B-BFF9-4423-8D73-63738C65C427Q28287576-CD827663-F606-4A36-ADC6-367914FF467EQ28290977-274351DF-30E8-459E-85BB-4BF8076AC74BQ28469102-D2062FF9-6996-45AA-BB7A-FD2DEE9284EDQ30469285-83EBB8D4-08FF-4E96-AFF8-EA9BDF32EBD6Q30479725-621810F0-9BB9-49BE-A400-7CCF856179DAQ33724801-3FB88020-173A-4D5B-BD8C-DF4CFB6E7ABFQ33804836-5653D092-270D-406E-AB43-7EFE7C40E6BAQ33839379-7BCD0BCB-92C5-4F24-B91D-B62096368D6FQ34026011-33BF2C58-4CE8-4CF8-BB4C-61D78079214FQ34274859-463BEEED-7A39-403F-8BC1-E92694B6F332Q34604423-3A59F531-A964-4F5A-9A77-9768B2E4865AQ34672123-BE40B26D-E3E1-4445-91F7-573F52526903Q35123842-7FC9ED15-FEAC-41A5-8752-873337D12729Q35738997-9673AF58-CC4D-4472-ADA8-66FD753D77C3Q36831744-73734FD5-60B8-47AF-978A-148C7D3EA81EQ36930839-1A9F6451-C6BE-4C51-B3C1-3B3A0DCB8651Q36989822-949E62C7-C888-415C-8E9C-C4A438509261Q36992322-9383297F-5C78-43FC-BBF0-43E4D0DF3B42Q37272791-E8DE7DFE-F32F-4093-AD92-57780671BAF7Q37287211-55C9C6A3-A85F-4318-A187-D47FFAC3EE23Q37349910-38EFA22B-2321-4DA3-91D9-5F54F0B3110AQ37575922-D455D045-D6A8-4ECE-A3B4-38271928378AQ37672827-9C9E933D-831A-4ACD-894A-0B3EBD80AB8CQ37760933-088D313D-8FFE-49AB-84C5-B040434E6475Q37975551-FC82AC06-F498-4640-81C9-A91A532A96AFQ38007928-281E77F2-E8E3-4F46-AA15-827688A8A971Q38110180-918B39E7-1217-4C3D-88F6-76473E650E5DQ38186705-6D9171F1-BF9D-4C9E-928B-C5E966F7E1EDQ38647035-852C1611-C6B2-440D-9F71-CBDC4D846FA5Q38819941-328EEA39-CF7A-4FA4-A230-1E8B0D71DE4BQ38966509-76681A87-31A0-4730-B05D-FD413C3D8C63Q39157511-7FAC1C58-F308-4066-8695-A97405BBDADEQ39220948-56FCD852-FDAF-47C1-9053-C618DE18A420Q43270061-0FC660ED-3C20-4F69-92DA-B4E78E4C2756Q44902190-CC8B4F01-1954-47B4-ABD4-C701F329155DQ46150844-6B037604-45C8-4DED-BACD-EA9880674BFAQ47302385-34087F2B-6C6A-4EBA-836C-404A9D603BD8Q47306872-3488AD3C-9852-42BC-8CFD-776201FBF78A
P2860
Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Pharmacological treatment of p ...... ophrenia: a systematic review.
@ast
Pharmacological treatment of p ...... ophrenia: a systematic review.
@en
type
label
Pharmacological treatment of p ...... ophrenia: a systematic review.
@ast
Pharmacological treatment of p ...... ophrenia: a systematic review.
@en
prefLabel
Pharmacological treatment of p ...... ophrenia: a systematic review.
@ast
Pharmacological treatment of p ...... ophrenia: a systematic review.
@en
P2093
P1476
Pharmacological treatment of p ...... ophrenia: a systematic review.
@en
P2093
Brendan P Murphy
Patrick D McGorry
Tae-Won Park
Young-Chul Chung
P356
10.1016/J.SCHRES.2006.07.002
P407
P577
2006-08-23T00:00:00Z